• PFS by RECIST and irRC. • OS. • DOR. • DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months). • PROs of pancreatic cancer symptom s. Exploratory Endpoints: • Determination of tumor genomic, transcriptomic, and proteomic profiles and correlations with subject outcomes. • Determination of PD-L1 expression from ct RNA and correlation with subject outcomes. Phase 2 Primary Endpoint : • ORR by RECIST and irRC. Secondary Endpoints: • PFS by RECIST and irRC. • OS.